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Abstract: Antimicrobial resistant bacteria are an increasing concern due to the resulting 
increase in morbidity, mortality, and health-care costs associated with the administration of 
inadequate or delayed antimicrobial therapy. The implications of inadequate antimicrobial 
therapy in   complicated skin and skin structure infections (cSSSIs) have gained more attention 
recently, most likely due to the recent emergence of community-acquired methicillin resistant 
Staphylococcus aureus (MRSA) and the already high prevalence of MRSA in the nosocomial 
setting. Due to the continuous threat of resistance arising and the limitations of currently 
  available agents for the treatment of cSSSIs, it is necessary to develop new antimicrobials for 
this indication. Ceftobiprole medocaril, the prodrug of ceftobiprole, is a parental investigational 
cephalosporin for the treatment of cSSSIs displaying a wide-spectrum of activity against both 
Gram-positive and Gram-negative species, including MRSA. Ceftobiprole displays noncom-
plex linear   pharmacokinetics, is eliminated primarily by glomerular filtration, and distributes 
to extracellular fluid. Additionally, it has been shown that the extent of distribution to the site 
of action with regard to cSSSIs, ie, the   extracellular space fluid of subcutaneous adipose tissue 
and skeletal muscle, is expected to be efficacious, as free concentrations meet efficacy targets 
for most pathogens. Similar to other beta-lactams, it displays an excellent safety and tolerability 
profile with the primary adverse events being dysgeusia in healthy volunteers, resulting from the 
conversion of the prodrug to the active, and nausea in patients. Ceftobiprole has demonstrated 
noninferiority in two large-scale pivotal studies comparing it to vancomycin, clinical cure rates 
93.3% vs 93.5%, respectively, or vancomycin plus ceftazidime, clinical cure rates 90.5% vs 
90.2%, respectively. Given the pharmacokinetic and pharmacodynamic properties, ceftobiprole 
is a promising new agent for the treatment of cSSSIs and has the potential to be used as a single 
agent for empiric treatment.
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Introduction
Antimicrobial resistant bacteria are an increasing concern due to the resulting increase 
in morbidity, mortality, and health-care costs associated with the administration of 
inadequate or delayed antimicrobial therapy.1–9 Proper guidelines should be followed 
to efficiently manage skin and skin structure infections and avoid the over usage of 
available antibiotics, which could possibly facilitate resistance development. The 
management of skin and skin structure infections is dependent on several factors. 
One factor is whether the infection is complicated or uncomplicated, as this dictates 
the need for antibiotics. Complicated infections are defined as infections involving 
deep soft tissues and usually require antimicrobial therapy and possibly surgical Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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intervention. Infections occurring in patients with signifi-
cant comorbidities, eg, diabetes or eczema, or in certain 
anatomical locations, eg, perianal, may also be considered 
complicated.10–13 Uncomplicated infections, however, are 
more superficial and less serious, eg, impetigo, cellulitis, 
and folliculitis.10,12,13 Typically, uncomplicated skin and soft 
tissue infections are effectively managed with   incision and 
drainage.14,15 The management of complicated infections is 
more complex and it is recommend that in addition to pos-
sible incision and drainage, the following be performed in 
order to optimize antimicrobial therapy; a detailed history, 
examination of the lesions as part of a physical exam, and 
administration of empiric antimicrobial therapy with adjust-
ment after microbiological identification of the pathogen(s).16 
These guidelines attempt to provide as much information 
as possible to health care providers so that optimal therapy 
can be started and treatment may be adjusted as additional 
information becomes available.
The selection of an empiric antibiotic with activity 
against the causative pathogen(s) is nevertheless, difficult 
due to   resistance and the wide-range of possible pathogens. 
For   example, Staphylococcus aureus and Pseudomonas 
  aeruginosa respectively, account for approximately 45% and 
11% of skin and soft tissue infections in North   America.17 
Despite these difficulties, selection of an   appropriate antibiotic 
in a timely fashion is imperative due to the negative outcomes 
associated with inadequate antimicrobial therapy (IAT). The 
impact of IAT has been extensively studied in pneumonia 
and   bloodstream infections due to the more severe clinical 
outcomes associated with these infections, ie, higher mortal-
ity rates.18 While there are some previous data that suggest 
that IAT results in negative outcomes in skin and soft tissue 
infections,7 the implications of IAT in complicated skin and 
skin structure infections (cSSSIs), including surgical site 
infections, have gained more attention recently.3,4,8
The high prevalence of methicillin resistant S. aureus 
in the nosocomial setting, or hospital-acquired MRSA 
(HA-MRSA), and the emergence of community-acquired 
methicillin-resistant S. aureus (CA-MRSA)19–21 is certainly 
a cause for concern and numerous studies have been con-
ducted to evaluate the impact of CA-MRSA in particular. 
Studies have examined whether or not there has been a 
correlation between physician visits and the emergence 
of CA-MRSA. The literature on the effect of CA-MRSA 
on overall ambulatory visits is controversial and therefore 
difficult to interpret. However, numerous studies do in fact 
show a correlation between the emergence of CA-MRSA 
and an increase in emergency department visits and/or visit 
rates due to skin and soft tissue infections.22–24 Subsequently, 
there may also be an increase in prescriptions for antibiotics 
with activity against CA-MRSA.22,25 However, this literature 
is also controversial.23,24 Despite contradictory reports, it can 
be definitively stated that with the emergence and prevalence 
of resistant species, particularly resistance in Staphylococcus 
species (Figure 1),12 and the negative impacts of IAT, there is 
a need to develop new antimicrobial therapeutic options.
Antimicrobial therapies  
for the treatment of cSSSIs
When selecting empiric therapeutic options for the treatment 
of cSSSIs, it is necessary to consider regional resistance 
patterns to make an appropriate treatment   recommendation. 
It has been recommended that for patients with skin and 
soft tissue infections (SSTIs) in regions where CA-MRSA 
  prevalence is greater than 10%–15%, alternatives to the 
commonly prescribed beta-lactams should be used.25,26 
Additionally, it has been suggested that due to resistance, 
ciprofloxacin, levofloxacin, and clindamycin, are no   longer 
viable empirical treatment options.27 Vancomycin has long 
been the standard empirical therapy for patients with   serious 
cSSSIs, as it   displays good activity against MRSA and other 
  Gram-positive organisms commonly implicated in these infec-
tions.   However, resistance to vancomycin is seen in Entero­
coccus species, .10%,17,28 and in a few case reports with 
S. aureus.29–31 In view of the problem of resistance,   several 
new therapeutic options have been recently   developed. How-
ever, many of these new   treatments have serious limitations 
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Figure 1 Trends in resistance among Gram-positive pathogens (1975–2004). MRSe: 
methicillin-resistant  S.  epidermidis.  vRe:  vancomycin-resistant  Enterococcus.  viSA: 
vancomycin-intermediate S. aureus. vRSA: vancomycin-resistant S. aureus. Reprinted with 
permission from Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated 
skin and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt). 
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including a narrow activity profile, eg, Gram-positive organ-
isms only, and/or serious side effects.
Quinupristin–dalfopristin has been approved for the 
  treatment of bacteremia due to vancomycin-resistant 
  Enterococcus   faecium and cSSSIs due to methicillin-
  susceptible S. aureus (MSSA) and Streptococcus 
pyogenes.32 However, it is not active against vancomycin-
resistant Enterococcus faecalis.32 Additionally, it is not 
indicated in infections against MRSA, although it has 
been suggested to be an acceptable treatment option33,34 
and displays an in vitro MIC90 # 1 mg/L.35–37 Finally, 
quinupristin–dalfopristin also bears a significant prob-
ability of myalgia as a side effect and requires a cen-
tral venous catheter for administration, which limits 
its use.34,38 Linezolid is another available agent for the 
treatment of Gram-positive infections, including MRSA. 
Like vancomycin, resistance to linezolid has occurred 
but is rare.39 A more detrimental limitation for selection 
of this agent is the cost; $1,677 for a 10-day treatment 
regimen.27 Additionally, this option does not have an 
optimal adverse event profile as a considerable frequency 
of serious adverse events is observed, eg, thrombocy-
topenia, peripheral neuropathy, and lactic acidosis.40 
Daptomycin has also been proven efficacious in cSSSIs 
but, like other previously mentioned agents, is not active 
against Gram-negative organisms.41 Myopathy may result 
due to treatment with daptomycin42 and, subsequently, 
alternative treatments may be better options in patients 
concomitantly on statins.27 Tigecycline is approved for the 
treatment of cSSSIs and has a wide-spectrum of activity 
including many resistant Gram-positive and Gram-nega-
tive pathogens, with the exception of P . aeruginosa.43–45 
Trials comparing tigecycline to vancomycin-aztreonam 
in patients with cSSSIs revealed that tigecycline has a 
significantly higher incidence of gastrointestinal events, 
including nausea and vomiting.46 However, most events 
were mild to moderate and did not lead to discontinua-
tion of therapy. Tigecycline is contraindicated in children 
and pregnant women as it has a tendency to accumulate 
in bone47,48 and cause bone and teeth discoloration.49 
The above examples describe some available treatment 
options for cSSSIs. To describe the pharmacokinetic and 
pharmacodynamic profile of each in full and evaluate the 
numerous additional therapeutic options, is beyond the 
scope of this paper and the reader is referred to several 
reviews.11,12,16,27,38,50,51
In view of the above examples, it is evident that there is a 
need to develop new antimicrobials for the treatment of cSSSIs 
which have activity against resistant Gram-positive and Gram-
negative species with acceptable safety and tolerability. One 
promising new treatment option is ceftobiprole, a parental 
cephalosporin antibiotic with a wide-spectrum of activity 
including several resistant species such as MRSA. This com-
pound has finished phase III trials for the indication cSSSIs 
but has not yet been FDA approved. This paper reviews the 
pharmacokinetic/pharmacodynamic (PK/PD) profile of cefto-
biprole with respect to its potential role in cSSSIs.
Ceftobiprole pharmacokinetics
Plasma concentrations
Ceftobiprole is available only as a parental agent and 
is   delivered as the water-soluble prodrug ceftobiprole 
  medocaril. It is supplied in single use vials as lyophilized 
powder corresponding to 500 mg of ceftobiprole, 666.6 
mg of the prodrug, and is reconstituted in water or 5% 
dextrose for injection. After reconstitution it is further 
diluted in 0.9% sodium chloride, 5% dextrose, or Lactated 
Ringer’s   solution for infusion. The stability and recom-
mended   storage conditions of ceftobiprole in each of these 
solutions varies and should be referenced.52 Once infused, 
the prodrug is converted to the active within seconds by 
type A   esterases.53 The protein binding of ceftobiprole 
has been cited as 16%–38%.53–55 Dose proportionality is 
displayed as   clearance, volume of distribution, and dose 
normalized AUC and Cmax are consistent in doses rang-
ing from 125–1000 mg.55,56 The currently recommended 
empirical dosing regimen of ceftobiprole for the treatment 
of cSSSIs is 500 mg every 8 hours as a 2-hour i.v. infusion 
for 7–14 days. In patients without diabetic foot infection 
and where gram-positive pathogens only have been docu-
mented, the recommended treatment regimen is 500 mg 
every 12 hours as a 1-hour i.v. infusion for 7–14 days.52 
Following empirical dosing, the Cmax is 33.0 mg/L and 
the AUC0-tau is 102 mg*hr/L.52,53,57 After a single 500 mg 
dose as a 1-hour infusion, the Cmax is 34.2 mg/L and the 
AUC0–∞ is 116 mg*hr/L.53 In a multiple dose study the 
accumulation of ceftobiprole was found to be negligible 
with a 12-hour dosing interval.55 Similarly, no significant 
accumulation occurs during an 8-hour dosing interval.52 
The pharmacokinetics in patients with cSSSI were similar 
to healthy volunteers as after dosing 750 mg every 12 hours 
the AUC0–∞ was 143 mg*hr/L compared to 165 mg*hr/L, 
respectively.53 In this study the half-life was somewhat lower 
in patients, 3.06 hours,   compared to in healthy volunteers, 
4.11 hours.53,58 However, in a separate study in healthy 
  volunteers, half-life was reported as 2.61 hours.54 It was Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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also found that gender does not affect systemic exposure of 
ceftobiprole if   normalized for body weight.53
volume of distribution/tissue distribution
Ceftobiprole is similar to other beta-lactams in that it 
  distributes primarily to extracellular fluid. The volume of 
distribution of ceftobiprole is approximately 18L, reported 
range of Vss 11L to 21.7L.56 Therefore, it would be assumed 
that ceftobiprole reaches the site of action to a significant 
degree, as most   bacterial pathogens reside in the extracel-
lular space fluid. To more accurately determine ceftobiprole’s 
  concentration at the site of action, a microdialysis study was 
conducted. In this study, concentrations were measured in 
subcutaneous soft tissues, ie, adipose tissue and skeletal mus-
cle. Concentrations in these tissues are particularly important 
to define the PK/PD relationship with regard to cSSSIs. It 
was found that the AUC ratios of free tissue/free plasma were 
0.69 and 0.49 for skeletal muscle and s.c. adipose tissue, 
respectively, demonstrating that ceftobiprole has the ability to 
penetrate into these tissues54 (Figure 2). Additionally, a study 
using radiolabeled   ceftobiprole was conducted in mice and 
rats to determine the tissue   distribution. It was shown that 
ceftobiprole distributed rapidly into tissues with the highest 
tissue/plasma ratio occurring in the kidney, 1:3, and did not 
penetrate into the brain, tissue/plasma ratio 0:01.52 However, 
the results from radiolabelled studies should be interpreted 
cautiously as only free drug at the site of action is active 
and this technique fails to differentiate between central and 
peripheral compartments.
Clearance
Ceftobiprole is primarily eliminated by glomerular filtration 
as clearance, range 4.46–5.99L/hr,56 is highly correlated 
to creatinine clearance53 and approximately equal to the 
  glomerular filtration rate multiplied by the unbound frac-
tion of ceftobiprole. The recovery of unchanged drug in 
the urine was measured in a single ascending dose study, 
dose range 125–1000 mg delivered as 0.5-hour infusions. 
It was determined that 62% to 78% of unchanged drug is 
recovered in urine of healthy volunteers over 24 hours.55 
After administration of ceftobiprole, 500 mg 2hr infusion 
q8hr, in healthy volunteers, $83% of the drug was found 
unchanged in the urine, while the primary metabolite, ie, 
the open-ring metabolite, represented ,7%.57 Ceftobiprole 
is not thought to be eliminated by active tubular secretion 
as demonstrated by a probenecid study or metabolism as 
preclinical and in vitro experiments showed no potential for 
CYP interactions.53 A dosing adjustment is recommended in 
patients with impaired renal function. Patients with a crea-
tinine clearance (Clcr) of 30 , 50 mL/min should have the 
dosing interval adjusted to every 12 hours. In patients with 
a Clcr , 30 mL/min, the dosing regimen should be 250 mg 
every 12 hours as a 2 hour i.v. infusion.52
Population pharmacokinetics
Several population PK models have been developed for 
ceftobiprole. Many of these models were developed for use 
in Monte Carlo simulations to aid in selection of the optimal 
dosing regimen. Additionally, these models allow identifica-
tion of significant covariates and show how these covariates 
affect the pharmacokinetics and, subsequently, safety and 
efficacy. In terms of resistance development, theses models 
can be used to predict the target attainment rate as susceptibil-
ity changes, eg, at increased MICs. Phase I data was fit to a 
two-compartment model to perform Monte Carlo simulations 
and identify an appropriate dosing regimen for phase II.59 
Data from phase I and II studies were used to develop a three-
compartment model with first-order elimination from the 
central compartment.60 In this model, a hydrolysis compart-
ment was included as the prodrug was infused at a constant 
rate into this compartment and then hydrolyzed to the active 
compound. The active drug entered the central compartment 
via a first-order process. The clearance was dependent on 
the creatinine clearance in this model. Later the predicted 
distribution of renal function was used to calculate the target 
attainment rate and determine the appropriate dosing regi-
men in patients with various degrees of renal function. Data 
from phase I, II, and III studies were modeled using a three 
Figure 2 Mean ceftobiprole concentration in plasma (circles), free plasma (dashed line), 
skeletal muscle (squares), and s.c. adipose tissue (triangles) over 12 h. Reprinted with 
permission from Barbour A, Schmidt S, Sabarinath SN, et al. Soft-tissue penetration 
of  ceftobiprole  in  healthy  volunteers  determined  by  in  vivo  microdialysis.  Antimicrob 
Agents  Chemother.  2009;53:2773–2776.54  Copyright  ©  2009  American  Society  for 
Microbiology.
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compartment model which included a central compartment 
and deep and shallow peripheral compartments. In this model, 
sex, body weight, creatinine clearance, and health status were 
identified as covariates.61 Finally, epithelial lining fluid (ELF) 
concentrations from healthy volunteers were used to develop 
a four-compartment model where ELF represented a separate 
compartment.62 This model was more directed at identifying 
the target concentration at the site of action, ie, ELF, for the 
indication of nosocomial pneumonia. The application of these 
models will be discussed in a later section.
Adverse events
In pivotal phase III trials, ceftobiprole had a safety and toler-
ability profile similar to competitors. In a study comparing 
ceftobiprole to vancomycin plus ceftazidime, 56% of patients 
in the ceftobiprole arm and 57% of patients in the comparator 
arm, experienced at least one adverse event (AE).63 Similarly, 
7% of patients in the ceftobiprole arm and 9% in the competitor 
arm had at least one serious AE. Four percent of patients from 
both arms had to discontinue treatment due to an AE. In a study 
comparing ceftobiprole to vancomycin, only 52% of patients 
in the ceftobiprole arm had at least one AE, compared to 
51% in the vancomycin arm.64 Four percent of patients in the 
ceftobiprole arm and 6% in the vancomycin arm discontinued 
treatment due to an AE. Six percent of subjects in either arm 
experienced an AE. Interestingly, dysgeusia was a common 
AE in the comparator trial with vancomycin and in trials with 
healthy volunteers but was not listed in the vancomycin plus 
ceftazidime trial. The most common AEs for ceftobiprole 
from single and multiple dose studies in healthy volunteers 
and comparator studies in patients are nausea, headache, 
dysgeusia, vomiting, diarrhea, constipation, hypersensitivity, 
and infusion site reaction. Dysgeusia is directly related to 
ceftobiprole   dosing and is thought to be due to the conver-
sion of ceftobiprole medocaril to the active, ceftobiprole, and 
diacetyl, which is known to produce a caramel-like odor.53,55,65 
The most common AEs in healthy volunteers and patients with 
cSSSIs are summarized in Table 1.55,63,64,66
Ceftobiprole pharmacodynamics
In vitro
Ceftobiprole, like other beta-lactams, binds to penicillin 
binding proteins (PBPs) and inhibits cell-wall synthesis. It 
has a wide-range of activity against gram-positive patho-
gens, including MRSA, and a pharmacodynamic profile 
similar to cefepime and ceftazidime against Gram-negative 
pathogens.67 The in vitro activity of ceftobiprole against 
isolates collected from cSSSIs during the phase III pivotal 
studies is presented in Table 2.68 One feature of ceftobiprole 
that makes it a more attractive therapeutic option over many 
other antibiotics is its activity against several resistant spe-
cies including MRSA. Ceftobiprole’s activity against MRSA 
is due to its strong affinity for PBP2a (PBP2’), the major 
cause of resistance to other beta-lactams.69,70 Additionally, 
ceftobiprole has been determined to be primarily bactericidal 
from in vitro time-kill studies71 and by demonstrating MBC/
MIC ratios of ,4 for a large majority of tested isolates.72 
Ceftobiprole, however, shows poor affinity for PBP5 and is 
therefore not active against E. faecium.70 Also, ceftobiprole 
is susceptible to some beta-lactamases which explains the 
wide range of MICs for P . aeruginosa, Klebsiella pneumo­
Table 1 Most common adverse events (Aes) in healthy volunteers 
and patients.55,63,64,66
Healthy volunteers  Patients
Total No. of subjects 42 932
Total No. of subjects  
with at least one Ae
21 507
Total No. of subjects with  
at least one serious Ae
0 63
Dysgeusia 17 30
Nausea 10 113
Headache 10 68
Abdominal pain 2 *
vomiting 1 61
Diarrhea 1 62
Constipation 0 33
Hypersensitivitya 0 49
infusion-site reaction 1 48
aincluding rash and pruritus.
Reprinted with permission from Barbour A, Schmidt S, Rand KH, Derendorf H. 
Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-
negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Int 
J Antimicrob Agents. 2009;34:1–7.56 Copyright © 2009 elsevier.
Table 2 In vitro susceptibility determined from isolates collected 
from cSSSis from phase iii trials with ceftobiprole68
MIC90 (mg/L) MIC range (mg/L)
MSSA 0.5 0.12–1
MRSA 2 0.25–4
Pseudomonas aeruginosa* .64 0.25–.64
Enterococcus faecalis 0.5 0.12–0.5
Enterococcus faecium#  # 2–.64
Escherichia coli 0.12 0.015–.64
Enterobacter cloacae .64 0.03–.64
Klebsiella pneumonia  32 0.03–.64
Streptococcus pyogenes 0.015 0.008–0.25
Streptococcus agalactiae 0.12 0.015–0.12
CoNS methicillin susceptible 0.5 0.015–1
CoNS methicillin-resistant  2 0.06–4
Proteus mirabilis 0.12 0.015–.64
*Pseudomonas aeruginosa ceftazidime-susceptible MiC90-16.70 #Three isolates collected.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
490
Barbour and Derendorf
nia, and Escherichia coli. For example, 38.7% of P . aerugi­
nosa are inhibited at an MIC # 1 mg/L, while 85.2% are 
inhibited at an MIC # 8 mg/L.73 Ceftobiprole is resistant to 
  hydrolysis by the TEM-1 and SHV-1 beta-lactamases, simi-
lar to the competitors cefepime and ceftazidime. However, 
it is susceptible to hydrolysis by P . aeruginosa displaying 
high expression of AmpC beta-  lactamases or the VIM-2 
carbapenemase and E. coli expressing KPC-2 carbapen-
emase or the CTX-M-15 extended-spectrum beta-lactamase 
(ESBL).74 The MIC90 against Klebsiella species and E. coli for 
  ceftobiprole was .8 mg/L, while the MIC90 of the carbapen-
ems ertapenem, imipenem, and meropenem were #0.5 mg/L 
in isolates confirmed as ESBL producing.73
The post-antibiotic effect (PAE), is a pharmacodynamic 
measurement that determines if there is any residual effect 
once the antimicrobial agent has been removed from the system 
after exposure to suprainhibitory antimicrobial concentrations. 
For ceftobiprole, PAEs for S. pneumoniae, S. aureus, and E. 
faecalis were 1.4–3.1 hours, 0–1.7 hours, and 0–0.9 hours, 
respectively.75 Perhaps a more useful in vitro   pharmacodynamic 
measurement is the post-antibiotic sub-MIC effect (PA-SME) 
as it measures the effect of subinhibitory concentrations after 
initial exposure to suprainhibitory concentrations. This situa-
tion more closely mimics the in vivo situation where there is 
fluctuation between doses. The PA-SME for S. pneumoniae, 
S. aureus, and E. faecalis were 4.8 . 10.3 hours, 1.5–9.6 hours, 
and 3.8 . 10.7 hours, respectively.75 Comparatively, in vivo 
PAEs were found to be 0–0.8 hours and 3.8–4.8 hours for 
S. pneumonia and S. aureus, respectively.76
Serial passage studies
Serial passage studies are often performed with inves-
tigational antimicrobials to evaluate the potential for 
resistance   development. When compared to imipenem, 
  ciprofloxacin, and linezolid, ceftobiprole displayed no 
  resistance   development using an initial inoculum of 
105 CFU/mL of S. aureus (3 MRSA and 1 MSSA) or against 
S. aureus 745 with an initial inoculum of 2 × 108 CFU/plate 
after six to eight passages.70 In a separate study, it was 
shown that after 50 passages resistance to ceftobiprole did 
not develop in 10 strains of S. aureus, including strains with 
methicillin and/or vancomycin resistance and coagulase 
negative strains with or without methicillin and/or vancomy-
cin resistance.77 The highest observed MIC occurred in the 
  vancomycin-  intermediate S. aureus (VISA) strain, 8 mg/L, 
and was four times the original MIC. Similarly, after 50 
passages, resistance to   ceftobiprole was also not observed in 
Haemophilus   influenzae, six beta-lactamase positive and two 
negative strains, or Moraxella catarrhalis, two   beta-lactamase 
positive strains.78 The highest increase in MIC was four times 
the original MIC which occurred in one strain of beta-lacta-
mase positive H. influenzae, 0.06 mg/L to 0.25 mg/L. One 
group was able to demonstrate the occurrence of resistance 
due to mutations in the mecA gene by transforming a mecA 
negative strain with a plasmid that carries the mutated gene 
or by the induction of mutations in the mecA transformed 
strain through serial passages with ceftobiprole.79 However, 
the high inoculum used to induce the mutations after serial 
passage is not likely to occur in a single patient for a sus-
tained period of time. Surprisingly, in this study, resistance 
also developed in the mecA negative strain, suggesting a 
chromosomal mechanism of resistance.
Animal models
The efficacy of ceftobiprole has also been evaluated in   several 
animal models, the most relevant for the indication of cSSSIs 
being the mouse abscess model and the murine skin   infection 
model. The peritonitis model will be briefly discussed as peri-
tonitis is often related to, or caused by,   surgical site infections, 
a subclass of cSSSIs. Also noteworthy is the thigh infection 
model which will be discussed further in the PK/PD section. 
Animal models which support possible other   indications 
including septicemia,70 endocarditis,80 and   pneumonia/
lung infections81,82 will not be discussed here. In the mouse 
abscess model, mice were inoculated with S. aureus I-6, a 
MRSA strain, or Mu50, a MRSA/VISA strain, under the 
skin of the groin with abscess developing within 3 days in 
control animals.70 Treatment was administered up to 3 hours 
after inoculation. Compared to vancomycin (10 mg/kg) 
and linezolid (20 mg/kg), ceftobiprole (10 mg/kg) treat-
ment resulted in a greater decrease in bacterial counts of 
MRSA I-6 from untreated controls, 3.42, 0.80, and 5.12 log 
decreases, respectively. Similarly, with VISA, ceftobiprole 
(10 mg/kg) demonstrated a larger decrease in log bacterial 
counts   compared to vancomycin (40 mg/kg) and linezolid 
(20 mg/kg), .4.79, 0.13, and 0.64, respectively,   displaying 
the efficacy of ceftobiprole compared to competitors   currently 
used to treat serious MRSA cSSSIs.
The murine skin infection model compared the activity 
of ceftobiprole to cefazolin, vancomycin, and linezolid 
against an MSSA and an MRSA strain in immuno-
competent mice.83 The activity of ceftobiprole was also 
compared to cefepime and meropenem-cilastatin against 
two P . aeruginosa strains, an inducible AmpC beta-
lactamase strain (OC4351) and an overproducing AmpC 
beta-lactamase strain (OC4354), in immunocompromised Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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mice.83 The mice were inoculated with 6.7–7.0 log10 CFU/
mouse of S. aureus or 5.9 to 6.8 log10 CFU/mouse of P. 
aeruginosa. After inoculation to the right (MRSA) and left 
(MSSA) flank, animals were treated with 1.6–100 mg/kg/
day at 1, 3, 25, and 27 hours post infection with ceftobi-
prole medocaril, cefazolin, vancomycin, or linezolid. One, 
2, 25, and 27 hours after inoculation to the left (OC 4351) 
and right (OC 4354) flanks with P . aeruginosa, animals 
were treated with ceftobiprole medocaril, cefepime, or 
meropenem-cilastatin with 1.6–100 mg/kg/day. The reduc-
tion of CFU/g of infected skin with MSSA and MRSA 
was greatest with ceftobiprole compared to comparators 
linezolid and cefazolin across all doses tested. Compared 
to vancomycin, ceftobiprole treatment resulted in a greater 
reduction in CFU/g for MSSA and MRSA at all doses, 
except the 100 mg/kg/day dose at which the decrease in 
CFU of MRSA/g was equivalent (-1.4 log10 change from 
inoculum). Similarly, ceftobiprole had a greater relative 
decrease in lesion volume compared to competitors for 
MSSA and MRSA at all doses, except MSSA with vanco-
mycin at the 100 mg/kg/day dose, lesion volumes of 555, 
437, 567, and 1181 mm3 for ceftobiprole, vancomycin, 
linezolid, and untreated controls respectively. Against 
both P . aeruginosa strains, ceftobiprole was as effica-
cious as meropenem-cilastatin and better than cefepime 
when comparing change in log10 CFU/g at doses of 25 
and 100 mg/kg/day. The log10 change in CFU/g at a dose 
of 100 mg/kg/day was -1.4, 1.7, -1.1 for ceftobiprole, 
cefepime, and meropenem-cilastatin, respectively, against 
OC4354. In terms of lesion size, ceftobiprole displayed 
a greater decrease from untreated controls than cefepime 
but displayed similar efficacy to meropenem-cilastatin. It 
should be noted that AmpC levels did not affect ceftobi-
prole efficacy. This study displayed the potential of ceftobi-
prole to be used as an empiric agent as it displayed efficacy 
against two of the most common cSSSI pathogens.
The efficacy of ceftobiprole was also compared to 
ampicillin, in the mouse Enterococcal peritonitis model.84 
Infections were induced using an initial inoculum that 
was 10 × the inoculum that caused death in half the popu-
lation (LD50). The strains used included four E. faecalis 
strains; one beta-lactamase producing (BLA+), two VRE, 
and one laboratory strain OG1RF. It was found that 
ceftobiprole displayed similar activity to ampicillin with 
a 50% protective dose (PD50) for ceftobiprole of 7.7 mg/
kg, 5.2 mg/kg, and 4.2 mg/kg compared to 12.5 mg/kg, 
16.4 mg/kg, and 8 mg/kg for ampicillin, against the two 
VRE strains and the OG1RF strain, respectively. Notably, 
ceftobiprole displayed a much lower PD50 compared to 
ampicillin against the Bla+ strain, 2 mg/kg compared   
to .100 mg/kg.
Comparator studies
Two large scale phase III pivotal studies have been conducted 
in patients with complicated skin and skin structure infections 
for ceftobiprole. Ceftobiprole was compared to vancomycin 
in patients with cSSSIs caused by Gram-positive pathogens.64 
In this study, 500 mg ceftobiprole or 1000 mg vancomycin 
were administered as 60 minute i.v. infusions ever 12 hours 
for 7 to 14 days. It was found that   ceftobiprole is   noninferior 
to vancomycin with clinical cure rates of 93.3% and 93.5%, 
respectively. In a separate study, the efficacy of ceftobiprole 
was compared to vancomycin plus ceftazidime in patients with 
cSSSI. In this study, patients in the ceftobiprole arm received 
500 mg of ceftobiprole administered as a 120-minute i.v. infu-
sion every 8 hours plus a 60-minute i.v. infusion of placebo. 
Patients in the vancomycin plus ceftazidime arm received 
1000 mg vancomycin over 60   minutes every 12 hours plus 
1000 mg of ceftazidime over 120 minutes every 8 hours.63 
It was found that ceftobiprole is noninferior to vancomycin 
plus ceftazidime as the clinical cure rates were 90.5% and 
90.2%, respectively.
While the role of PVL as a virulence factor in MRSA 
infections is controversial, it is agreed that PVL is associ-
ated with community-acquired infections and, as previ-
ously mentioned, the increasing frequency of CA-MRSA 
  infections is correlated to a subsequent increase in ED 
visits. Therefore, it is interesting to note that ceftobiprole 
had a higher clinical cure rate compared to vancomycin in 
MRSA PVL-positive infections, 93.1% (27/29) compared 
to 84.6% (22/26), although this finding was not   statistically 
  significant.64 Similarly, ceftobiprole had a higher clinical 
cure rate for PVL-positive isolates compared to   vancomycin 
plus ceftazidime, 92.1% (35/38) compared to 84.2% 
(16/19).63
Ceftobiprole pharmacokinetics/
pharmacodynamics
establishing pharmacokinetic/
pharmacodynamic targets
The PK/PD relationship has been established in the mouse 
thigh and lung infection models.82 The more relevant targets 
for cSSSI would be those established from the thigh infection 
model and, therefore, the results from these experiments will be 
the main focus. Dose fractionation studies in neutropenic mice, Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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with doses ranging from 0.01 mg/kg to 160 mg/kg administered 
every 3, 4, 6, 8, 12 and/or 24 hours 2 to 10 hours after infec-
tion, were used to determine the best correlated PK/PD index 
and the magnitude of that index resulting in bacterial stasis or 
a 2-log kill. These studies were performed using 19 bacterial 
strains including S. aureus (MSSA and MRSA), S. pneumo­
niae (PSSP, PRSP, and one ciprofloxacin-resistant strain), E. 
coli, K. pneumoniae, Enterobacter cloacae, and P . aeruginosa. 
From the dose-response curves of the thigh infection model, it 
was found that the T . MIC needed to produce a static effect 
and 2-log were 19.8% and 31.9%, respectively, for S. aureus, 
and 15.9% and 25.1%, respectively, for S. pneumoniae. As 
typical, a larger magnitude of the PK/PD target was needed 
to produce stasis and 2-log kill with Gram-negative species, 
36.5% and 54.3%, respectively. These identified targets are in 
good agreement with the targets currently known to produce 
efficacy for beta-lactams in both animal models and in the 
clinic.85–87 Additionally, a CART analysis showed that patients 
with a T . MIC of 25% had a higher probability of therapeutic 
success, further validating the identified efficacy targets.88
Dose selection/evaluation
The targets identified from dose fractionation studies are often 
used to predict efficacy using Monte Carlo simulations to find 
the target attainment rate (TAR). Monte Carlo simulations take 
variability of the PK, such as inter-patient variability, and PD, 
ie, the MIC distribution, into account when calculating the 
TAR. This technique has been used numerous times for the 
dose selection and dose   evaluation for ceftobiprole. In addition 
to the targets set by dose   fractionation experiments, empirical 
targets are also used as antibiotics in the same class often have 
approximately the same target. For example, a general PK/PD 
target for beta-lactams is approximately 40% fT.MIC. However, 
even among beta-lactam antibiotics the efficacy target varies 
between subgroups, ie, cephalosporins,   penicillins, and carbap-
enems, and specific pathogens.85–87 Monte Carlo   simulations 
were performed first using PK data from 12 healthy volunteers, 
where the TAR for the PK/PD targets of fT.MIC 30%–60% were 
calculated for numerous doses, 250–1000 mg administered 
every 12 or 8 hours.59 From these simulations it was concluded 
that a 750 mg dose given every 12 hours had a high probability 
of efficacy for organisms with MICs up to 4 mg/L. Monte 
Carlo simulations were later performed using a larger and more 
diverse patient population.89 In these simulations, the PK was 
characterized using data from 150 subjects from both phase I 
and phase II trials. Doses of 500 mg every 8 hours delivered as 
0.5-, 1-, or 2-hour i.v. infusions and 500 mg every 12 delivered 
as a 1-hour i.v. infusion were simulated to determine the TAR 
for targets of 30%–60% f T.MIC. Additionally, the TAR was 
calculated in patients with renal impairment, Clcr = 30 mL/min 
dosed with 250 mg every 8 hours as a 2-hour i.v. infusion, and 
Clcr = 50 mL/min dosed with 500 mg every 12 hours as a 2-hour 
i.v. infusion. Based on these simulations, 500 mg administered 
as a 1-hour i.v. infusion every 12 hours was recommended for 
the indication of cSSSIs. Also, a dosing regimen of 500 mg as 
a 2-hour i.v. infusion every 8 hours was deemed an appropri-
ate dose in patients with mild to moderate renal impairment, 
ie, a Clcr∼50 mL/min. Finally, simulations were done using a 
model that was developed using data from phase I, II, and III 
trials and the individual patient demographics from patients in 
the phase III trials using a dosing regimen of 500 mg every 8 
hours as a 2-hour i.v. infusion.61 It was found that the overall 
TAR for targets of fT.MIC 30% and 50% were 94.6% and 93.7%, 
respectively, based on the MIC distribution and a creatinine 
clearance of $80 mL/min.88 The dose of 500 mg delivered as 
a 2-hour infusion was also validated in the microdialysis study 
where it was found that concentrations in the extracellular fluid 
of s.c. adipose tissue and skeletal muscle met the PK/PD target 
of fT.MIC 40% for organisms with a MIC # 2 mg/L.54
Discussion
In North America, 44.6% of SSTIs are caused by S. aureus, of 
which 35.9% are methicillin-resistant.17 The second most com-
monly identified pathogen, P . aeruginosa, accounts for 11.1% 
of SSTIs, while the third and fourth most commonly isolated 
pathogens were Enterococcus species (9.3%) and E. coli (7.2%), 
respectively. Additionally, cSSSIs can be polymicrobial and include 
both Gram-positive and Gram-negative pathogens, eg, diabetic foot 
infections. Therefore, due to the wide-spectrum of causative patho-
gens and various resistance mechanisms, an obvious challenge 
arises in identifying a first-line single agent or even combination 
therapy for empiric treatment prior to microbial identification. 
Based on its activity profile, ceftobiprole has the potential to serve 
as a single agent for the empiric treatment of cSSSIs. However, 
pathogen identification and characterization is still needed as cefto-
biprole is susceptible to some beta-lactamases. For example, while 
activity is observed against E. coli, MIC90 0.12 mg/L, in species 
producing ESBLs (∼6%),17,67 the MIC90 is reported as .8 mg/L.67 
Additionally, ceftobiprole does not display good activity against 
E. faecium.70 Another minor limitation of ceftobiprole, is that the 
mechanism of action does not inhibit protein synthesis as some 
competitors. Down regulating PVL, a possible virulence factor, 
could be advantageous in CA-MRSA infections.27
In conclusion, ceftobiprole has several characteristics 
that make it a promising single agent for use empiri-
cally to treat cSSSIs including its spectrum of activity, Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
493
Role of ceftobiprole for cSSSis
distributional properties, and excellent safety and 
tolerability profile.
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